Cargando…
Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
COVID 19 pandemic and mass vaccination campaigns have revealed the situation of the most vulnerable patients. In this work, we focused our attention to patients who have Multiple Sclerosis (MS), particularly in treatment with cladribine tablets, trying to understand if and when it is possible to adm...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886810/ https://www.ncbi.nlm.nih.gov/pubmed/34923946 http://dx.doi.org/10.2174/1570159X20666211217160451 |
_version_ | 1784880199322566656 |
---|---|
author | Moiola, Lucia Riva, Agostino Nicoletti, Ferdinando Uccelli, Antonio Salvetti, Marco Battistini, Luca Furlan, Roberto |
author_facet | Moiola, Lucia Riva, Agostino Nicoletti, Ferdinando Uccelli, Antonio Salvetti, Marco Battistini, Luca Furlan, Roberto |
author_sort | Moiola, Lucia |
collection | PubMed |
description | COVID 19 pandemic and mass vaccination campaigns have revealed the situation of the most vulnerable patients. In this work, we focused our attention to patients who have Multiple Sclerosis (MS), particularly in treatment with cladribine tablets, trying to understand if and when it is possible to administer the vaccine successfully. In light of the novel topic, we studied the existing literature and analysed experiences with previous vaccinations, such as influenza and VZV, as well as data from countries where vaccination campaigns had already begun. Overall, we have taken into account the mechanism of action, the pharmacokinetic/pharmacodynamic of cladribine, and the changes in the immune system after its administration, together with the preliminary data about the humoral response to influenza, VZV, and SARS-CoV-2 vaccinations in cladribine treated patients. In conclusion, data showed that the use of cladribine tablets seems to permit flexibility regarding vaccination timing and we suggest that vaccination in those patients should be safe and effective. The current COVID 19 pandemic has re-ignited the interest in vaccines and vaccination procedures. The importance of including fragile individuals has increased as a result of mass vaccination. Millions of patients with multiple sclerosis (MS) around the world are debating whether they can safely receive their vaccine shot with the same efficacy despite receiving immune-modulating or immune-suppressive treatments. In the absence of conclusive empirical data, we will review and discuss the available evidence and the reasonable conclusions for one specific treatment, namely cladribine tablets (Mavenclad). |
format | Online Article Text |
id | pubmed-9886810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-98868102023-02-28 Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets Moiola, Lucia Riva, Agostino Nicoletti, Ferdinando Uccelli, Antonio Salvetti, Marco Battistini, Luca Furlan, Roberto Curr Neuropharmacol Neurology COVID 19 pandemic and mass vaccination campaigns have revealed the situation of the most vulnerable patients. In this work, we focused our attention to patients who have Multiple Sclerosis (MS), particularly in treatment with cladribine tablets, trying to understand if and when it is possible to administer the vaccine successfully. In light of the novel topic, we studied the existing literature and analysed experiences with previous vaccinations, such as influenza and VZV, as well as data from countries where vaccination campaigns had already begun. Overall, we have taken into account the mechanism of action, the pharmacokinetic/pharmacodynamic of cladribine, and the changes in the immune system after its administration, together with the preliminary data about the humoral response to influenza, VZV, and SARS-CoV-2 vaccinations in cladribine treated patients. In conclusion, data showed that the use of cladribine tablets seems to permit flexibility regarding vaccination timing and we suggest that vaccination in those patients should be safe and effective. The current COVID 19 pandemic has re-ignited the interest in vaccines and vaccination procedures. The importance of including fragile individuals has increased as a result of mass vaccination. Millions of patients with multiple sclerosis (MS) around the world are debating whether they can safely receive their vaccine shot with the same efficacy despite receiving immune-modulating or immune-suppressive treatments. In the absence of conclusive empirical data, we will review and discuss the available evidence and the reasonable conclusions for one specific treatment, namely cladribine tablets (Mavenclad). Bentham Science Publishers 2022-08-31 2022-08-31 /pmc/articles/PMC9886810/ /pubmed/34923946 http://dx.doi.org/10.2174/1570159X20666211217160451 Text en © 2022 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Neurology Moiola, Lucia Riva, Agostino Nicoletti, Ferdinando Uccelli, Antonio Salvetti, Marco Battistini, Luca Furlan, Roberto Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets |
title | Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets |
title_full | Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets |
title_fullStr | Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets |
title_full_unstemmed | Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets |
title_short | Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets |
title_sort | vaccination opportunities in multiple sclerosis patients treated with cladribine tablets |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886810/ https://www.ncbi.nlm.nih.gov/pubmed/34923946 http://dx.doi.org/10.2174/1570159X20666211217160451 |
work_keys_str_mv | AT moiolalucia vaccinationopportunitiesinmultiplesclerosispatientstreatedwithcladribinetablets AT rivaagostino vaccinationopportunitiesinmultiplesclerosispatientstreatedwithcladribinetablets AT nicolettiferdinando vaccinationopportunitiesinmultiplesclerosispatientstreatedwithcladribinetablets AT uccelliantonio vaccinationopportunitiesinmultiplesclerosispatientstreatedwithcladribinetablets AT salvettimarco vaccinationopportunitiesinmultiplesclerosispatientstreatedwithcladribinetablets AT battistiniluca vaccinationopportunitiesinmultiplesclerosispatientstreatedwithcladribinetablets AT furlanroberto vaccinationopportunitiesinmultiplesclerosispatientstreatedwithcladribinetablets |